All In Biotech

Drug Trial Radar · NCT05731843

Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir

A Phase 1, Open-Label Study to Evaluate the Potential Drug-Drug Interaction Between Bemnifosbuvir and Ruzasvir and Food-Drug Interaction in Healthy Adult Subjects

Last checked: Nov 20, 2026Latest source record: Jun 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Jan 30, 2023

Primary completion

Mar 15, 2023

Study completion Mar 15, 2023

Sponsor

Lead sponsor
Atea Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Feb 16, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Drug-drug interaction study of Ruzasvir and Bemnifosbuvir

Conditions

  • Healthy Volunteer Study

Interventions

  • Cohort 1 BEM + RuzasvirDrug

    Days 1 to 6 BEM under fasting conditions. Days 7 to 12 of BEM and Ruzasvir coadministered under fasting conditions. Days 13 to 18 of BEM and Ruzasvir coadministered under fed conditions

  • Cohort 2 Ruzasvir + BEMDrug

    Days 1 to 6 of Ruzasvir under fasting conditions. Days 7 to 12 of Ruzasvir and BEM coadministered under fasting conditions. Days 13 to 18 of Ruzasvir and BEM coadministered under fed conditions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK) of BEMTime frame: Days 6, 12, 18
  2. Pharmacokinetics (PK) of RuzasvirTime frame: Days 6, 12, 18

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Atea Study Site

    Québec, Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.